UNSPSC 51141569: Nafimidone

This classification denotes an anticonvulsant agent with the molecular formula C15H12N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HZU3IQ1EWW, chemically known as 2-imidazol-1-yl-1-naphthalen-2-ylethanone but generally known as nafimidone, which bears US NIH Compound Identifier 51200. European Medicines Agency schedules nafimidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09122MIG. The term NAFIMIDONE is an International Non-Proprietary Name or INN.

Most nations schedule nafimidone under HS 29332990 and SITC 51573. As of Q4 2014, NAFIMIDONE remains the US FDA Preferred Term for this commodity. SMILES: C1=CC=C2C=C(C=CC2=C1)C(=O)CN3C=CN=C3.

UNSPSC 51141569 Nafimidone is a Commodity code that covers pharmaceutical products and related medical supplies procured by state and local health agencies, though recent solicitations tagged under this code reflect a broader pattern of opioid-reversal agents, generic pharmaceuticals, and over-the-counter products rather than nafimidone specifically. State and local buyers under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work ranges from direct procurement of naloxone units and drug deactivation systems for community health initiatives to large-scale manufacturer contracting for multi-source generic pharmaceuticals distributed through authorized wholesale channels to state agencies and participating local government facilities.

Recent activity centers in Florida and Minnesota, with emerging interest from Texas state agencies. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the County Community Health Building and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, including Oregon, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026; evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent combined on administrative compliance, EDI capability, and other operational factors. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for self-insured employer and state agency contracting outside traditional pharmacy benefit manager and group purchasing organization arrangements.